U.S. Markets close in 4 hrs 46 mins

Evofem Biosciences, Inc. (EVFM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5600+0.2000 (+8.47%)
As of 11:14AM EDT. Market open.

Evofem Biosciences, Inc.

12400 High Bluff Drive
Suite 600
San Diego, CA 92130
United States
858 550 1900

Full Time Employees53

Key Executives

NameTitlePayExercisedYear Born
Ms. Saundra PelletierPres, CEO & Director1.91MN/A1970
Mr. Justin J. FileChief Financial Officer886.51kN/A1970
Mr. Russell BarransChief Commercial Officer678.57kN/A1960
Mr. Richard MurawskiSr. VP of OperationsN/AN/A1948
Mr. Mark KowieskiVP of Fin. & AccountingN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Corporate Governance

Evofem Biosciences, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.